99%(79)78 out of 79 people found this document helpful
This preview shows page 1 - 3 out of 7 pages.
1Running head: ASSESSING AND TREATING CLIENTS WITH DEMENTIAAssessing and Treating Clients With DementiaWalden UniversityNURS -6630, Psychopharmacologic Approaches to Treatment of PsychopathologyFebruary , 2019IntroductionDementia is a general term for a decline in mental ability severe enough to interfere with daily life such as memory loss (Alzheimer’s Association, 2019). Stahl (2013), also defines dementia as consisting of memory impairment (amnesia) plus deficits in either language (aphasia), motor function (apraxia), recognition (agnosia), or executive function such as workingmemory and problem solving; however, personality changes can be present even before memory impairment begins. Alzheimer’s disease (AD) is a progressive neurodegenerative condition. It is one of the most common forms of dementia which causes problems with a person’s memory and ability to learn, reason, make judgments, communicate and carry out daily activities (American Psychiatric Association [APA], 2018). There is currently no cure for Alzheimer’s disease, although treatment can help manage symptoms in some people; therefore early treatment may
2ASSESSING AND TREATING CLIENTS WITH DEMENTIAhelp preserve daily functions while providing people with comfort, dignity, and independence fora long period (National Institute on Aging, 2018).The case study for this assignment is on a 76-year-old Iranian male brought in by his eldest son for “strange behavior.” Son reports these strange thoughts and behaviors have been going on for the past two years and seems to be getting worse. The family has noticed a change in his personality like him losing interest in religious activities, being more critical of everyone and does not take things seriously anymore, becoming very forgetful, and finding it difficult to put the right words together and then shifts to a different topic of conversation. According to the mini-mental exam, this client scored 18 out of 30 showing some deficit in orientation, registration, attention & calculation, and recall which is indicative of moderate dementia. The purpose of this paper is to show how to assess and develop personalized therapy plans for clients with dementia based on the decision concerning the medication to prescribe to this client, the influence of pharmacokinetic and pharmacodynamic, and including ethical and legal implications related to prescribing therapy for clients with dementia. Decision OneThe first decision selected is to begin Aricept (donepezil) 5 mg orally at bedtime. Aricept belongs to a drug class called Cholinesterase inhibitors (ChEIs) is approved by the U.S. Food and Drug Administration (FDA) to treat the cognitive symptoms such as memory loss,